Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status:
Completed
Trial end date:
2021-09-20
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if regorafenib can help control or decrease cancer
size in patients with cancer of the bile duct. Researchers also want to find out if
regorafenib is safe and tolerable.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute